VBS Share Price Performance
Recent VBS News & Updates
No updates
Vectus Biosystems Limited Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.042
- Gross Margin
- 100.00%
- Net Profit Margin
- -255.56%
- Debt/Equity Ratio
- 0%
Vectus Biosystems Limited Competitors
About VBS
- Founded
- 2005
- Employees
- n/a
- CEO
- WebsiteView website
Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for cardiovascular fibrosis and systolic blood pressure, as well as treatments for kidney, liver, and lung fibrosis. Its lead compound is VB0004, currently under phase Ib clinical human trial, which is aimed at treating the loss of functional tissue to fibrosis, scarring, and high blood pressure; VB4-A32 for the treatment of liver fibrosis; VB4-A79 for the treatment of lung fibrosis; and VB4-P5 for the treatment of renal fibrosis. The company also intends to develop candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis and pulmonary fibrotic diseases. In addition, it develops Accugen consisting of AccuCal and RealCount software that enhance speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories. The company was incorporated in 2005 and is based in Rosebery, Australia.
Australian Market Performance
- 7 Days: 0.1%
- 3 Months: 7.9%
- 1 Year: 7.8%
- Year to Date: 6.3%
Over the last 7 days, the market has remained flat, although notably the Materials sector declined by 3.1%. More promisingly, the market is up 7.8% over the past year. Earnings are forecast to grow by 11% annually. Market details ›
Companies across the globe are beginning to pay attention to agentic AI. It’s also a term you’re likely to hear a lot during earnings season. In fact, it came up 26 times during...
Continue reading